A Multicenter, Open-label, Uncontrolled Phase II Study to Investigate Efficacy and Safety of ONO4538 in Patients With Rhabdoid Tumor
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Healthy Volunteers: f
View:
• Gender: Not specified
• Age (at the time of consent): 1 year or older
• Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
• Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection
Locations
Other Locations
Japan
National Cancer Center Hospital
RECRUITING
Chuo-ku
Nagoya University Hospital
RECRUITING
Nagoya
Osaka City General Hospital
RECRUITING
Osaka
Contact Information
Primary
North America Clinical Trial Support Desk
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
Backup
International Clinical Trial Support Desk
clinical_trial@ono-pharma.com
+17162141777(Standard)
Time Frame
Start Date: 2024-11-25
Estimated Completion Date: 2030-03-31
Participants
Target number of participants: 23
Treatments
Experimental: ONO-4538
Related Therapeutic Areas
Sponsors
Leads: Ono Pharmaceutical Co. Ltd